托西利祖马布在COVID-19:一个双刃剑?
Bartosz Kudliński1, Jacek Zawadzki1, Wiktoria Kulińska1
1Department of Anesthesia, Critical Care and Rescue Medicine, Collegium Medicum, University in Zielona Góra, 65-046 Zielona Góra, Poland.
托西利祖马布和类固醇改善了重症COVID-19 ARDS患者在ICU中的生存率. 尽管感染风险增加,这种细胞因子风暴治疗是安全有效的.
科学领域:
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 严重的COVID-19往往导致急性呼吸系统应急综合征 (ARDS),需要密集护理.
- 细胞因子风暴是严重COVID-19中ARDS的主要驱动因素.
- 使用免疫抑制疗法,如类固醇和托西利祖马布,但可能会增加感染风险.
研究的目的:
- 评估免疫抑制剂对严重COVID-19ARDS患者的生存的影响.
- 评估二次感染和患者结果之间的关系.
- 为了确定托西利祖马布在控制细胞因子风暴中的安全性和有效性.
主要方法:
- 分析了342名ICU患者的队列,其中包括需要机械通风的COVID-19归因ARDS的ICU患者.
- 根据免疫调节疗法 (类固醇,托西利祖马布或联合疗法) 和感染培养结果对患者进行了分类.
- 在不同治疗组和并发症中比较了生存率.
主要成果:
- 联合托西利祖马布和类固醇治疗显示了最高的生存率,特别是在61岁以下的患者中.
- 诸如心房动和冠心病等并发症与较低的存活率有关.
- 托西利祖马布使用增加了阳性病原体培养,但与这些患者的更高生存率有关.
结论:
- 机械通风,ICU护理和tocilizumab显著降低了严重的COVID-19 ARDS中的死亡率.
- 抑制细胞因子风暴对于改善生存至关重要.
- 托西利祖马布 (tocilizumab) 证明了有效性和安全性,即使有积极的二次感染培养物的风险增加.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
09:43Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)